Using health technology assessment to inform insurance reimbursement of high technology medicines in China: an example of cancer immunotherapy

Yingyao Chen and colleagues examine what can be learnt from China’s approach to funding expensive high technology medicines with uncertain long term benefit

Detalles Bibliográficos
Autores principales: Chen, Yingyao, Dong, Hengjin, Wei, Yan, Yang, Yi, Ming, Jian, Yu, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2023
Materias:
Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266439/
https://www.ncbi.nlm.nih.gov/pubmed/37321628
http://dx.doi.org/10.1136/bmj-2022-069963
_version_ 1785058741202190336
author Chen, Yingyao
Dong, Hengjin
Wei, Yan
Yang, Yi
Ming, Jian
Yu, Hao
author_facet Chen, Yingyao
Dong, Hengjin
Wei, Yan
Yang, Yi
Ming, Jian
Yu, Hao
author_sort Chen, Yingyao
collection PubMed
description Yingyao Chen and colleagues examine what can be learnt from China’s approach to funding expensive high technology medicines with uncertain long term benefit
format Online
Article
Text
id pubmed-10266439
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group Ltd.
record_format MEDLINE/PubMed
spelling pubmed-102664392023-06-15 Using health technology assessment to inform insurance reimbursement of high technology medicines in China: an example of cancer immunotherapy Chen, Yingyao Dong, Hengjin Wei, Yan Yang, Yi Ming, Jian Yu, Hao BMJ Analysis Yingyao Chen and colleagues examine what can be learnt from China’s approach to funding expensive high technology medicines with uncertain long term benefit BMJ Publishing Group Ltd. 2023-06-15 /pmc/articles/PMC10266439/ /pubmed/37321628 http://dx.doi.org/10.1136/bmj-2022-069963 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Analysis
Chen, Yingyao
Dong, Hengjin
Wei, Yan
Yang, Yi
Ming, Jian
Yu, Hao
Using health technology assessment to inform insurance reimbursement of high technology medicines in China: an example of cancer immunotherapy
title Using health technology assessment to inform insurance reimbursement of high technology medicines in China: an example of cancer immunotherapy
title_full Using health technology assessment to inform insurance reimbursement of high technology medicines in China: an example of cancer immunotherapy
title_fullStr Using health technology assessment to inform insurance reimbursement of high technology medicines in China: an example of cancer immunotherapy
title_full_unstemmed Using health technology assessment to inform insurance reimbursement of high technology medicines in China: an example of cancer immunotherapy
title_short Using health technology assessment to inform insurance reimbursement of high technology medicines in China: an example of cancer immunotherapy
title_sort using health technology assessment to inform insurance reimbursement of high technology medicines in china: an example of cancer immunotherapy
topic Analysis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266439/
https://www.ncbi.nlm.nih.gov/pubmed/37321628
http://dx.doi.org/10.1136/bmj-2022-069963
work_keys_str_mv AT chenyingyao usinghealthtechnologyassessmenttoinforminsurancereimbursementofhightechnologymedicinesinchinaanexampleofcancerimmunotherapy
AT donghengjin usinghealthtechnologyassessmenttoinforminsurancereimbursementofhightechnologymedicinesinchinaanexampleofcancerimmunotherapy
AT weiyan usinghealthtechnologyassessmenttoinforminsurancereimbursementofhightechnologymedicinesinchinaanexampleofcancerimmunotherapy
AT yangyi usinghealthtechnologyassessmenttoinforminsurancereimbursementofhightechnologymedicinesinchinaanexampleofcancerimmunotherapy
AT mingjian usinghealthtechnologyassessmenttoinforminsurancereimbursementofhightechnologymedicinesinchinaanexampleofcancerimmunotherapy
AT yuhao usinghealthtechnologyassessmenttoinforminsurancereimbursementofhightechnologymedicinesinchinaanexampleofcancerimmunotherapy

Ejemplares similares